Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (SHG:605016) — Stock Price
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (SHG:605016) is currently trading at CN¥21.84 CNY, up 2.39% today. Over the past 52 weeks, shares have ranged between CN¥18.88 and CN¥28.42. This page tracks Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Shandong Bailong Chuangyuan Bio-Tech Co..
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Income Statement — Revenue, Profit & Earnings by Year
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥1.38 Billion | CN¥1.15 Billion | CN¥868.26 Million | CN¥721.89 Million | CN¥653.36 Million |
| Cost of Revenue | CN¥803.18 Million | CN¥764.89 Million | CN¥584.20 Million | CN¥493.41 Million | CN¥471.72 Million |
| Gross Profit | CN¥575.87 Million | CN¥386.76 Million | CN¥284.06 Million | CN¥228.49 Million | CN¥181.64 Million |
| Research & Development | CN¥48.82 Million | CN¥44.46 Million | CN¥32.56 Million | CN¥27.03 Million | CN¥23.26 Million |
| SG&A | CN¥34.90 Million | CN¥33.41 Million | CN¥21.37 Million | CN¥20.60 Million | CN¥20.04 Million |
| Total Operating Expenses | CN¥930.56 Million | CN¥101.63 Million | CN¥60.37 Million | CN¥52.00 Million | CN¥61.39 Million |
| Operating Income | CN¥448.50 Million | CN¥285.13 Million | CN¥223.69 Million | CN¥176.48 Million | CN¥120.25 Million |
| EBITDA | — | CN¥334.22 Million | CN¥238.38 Million | CN¥192.42 Million | CN¥156.51 Million |
| EBIT | — | CN¥258.84 Million | CN¥193.45 Million | CN¥145.68 Million | CN¥109.98 Million |
| Interest Expense | CN¥5.77 Million | CN¥2.92 Million | CN¥2.43 Million | CN¥196.69K | CN¥1.18 Million |
| Income Before Tax | CN¥432.27 Million | CN¥285.31 Million | CN¥221.52 Million | CN¥173.09 Million | CN¥118.77 Million |
| Income Tax Expense | — | CN¥39.71 Million | CN¥28.52 Million | CN¥22.34 Million | CN¥14.29 Million |
| Net Income | CN¥368.55 Million | CN¥245.60 Million | CN¥193.00 Million | CN¥150.75 Million | CN¥104.48 Million |
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥2.44 Billion | CN¥2.01 Billion | CN¥1.75 Billion | CN¥1.47 Billion | CN¥1.28 Billion |
| Total Current Assets | CN¥1.14 Billion | CN¥901.46 Million | CN¥773.74 Million | CN¥855.54 Million | CN¥831.89 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥20.09 Million | CN¥152.27 Million | CN¥252.70 Million | CN¥330.00 Million | CN¥248.35 Million |
| Net Receivables | CN¥294.97 Million | CN¥240.90 Million | CN¥174.27 Million | CN¥154.83 Million | CN¥145.07 Million |
| Inventory | CN¥287.39 Million | CN¥186.83 Million | CN¥152.05 Million | CN¥167.71 Million | CN¥121.82 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥475.19 Million | CN¥334.27 Million | CN¥246.35 Million | CN¥126.99 Million | CN¥79.05 Million |
| Total Current Liabilities | CN¥363.78 Million | CN¥302.45 Million | CN¥241.70 Million | CN¥121.11 Million | CN¥71.21 Million |
| Long-term Debt | CN¥79.06 Million | — | — | — | — |
| Net Debt | — | CN¥-275.82 Million | CN¥-174.21 Million | CN¥-190.24 Million | CN¥-302.73 Million |
| Total Stockholder Equity | CN¥1.96 Billion | CN¥1.68 Billion | CN¥1.51 Billion | CN¥1.34 Billion | CN¥1.20 Billion |
| Retained Earnings | CN¥1.05 Billion | CN¥801.88 Million | CN¥656.81 Million | CN¥513.33 Million | CN¥388.38 Million |
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥135.45 Million | CN¥300.89 Million | CN¥194.63 Million | CN¥149.82 Million | CN¥96.20 Million |
| Capital Expenditures | CN¥296.80 Million | CN¥281.81 Million | CN¥311.98 Million | CN¥175.60 Million | CN¥55.82 Million |
| Free Cash Flow | CN¥-161.35 Million | CN¥19.09 Million | CN¥-117.34 Million | CN¥-25.78 Million | CN¥40.38 Million |
| Investing Cash Flow | — | CN¥-172.89 Million | CN¥-223.72 Million | CN¥-246.90 Million | CN¥-297.69 Million |
| Financing Cash Flow | — | CN¥-70.35 Million | CN¥-34.12 Million | CN¥-13.07 Million | CN¥362.36 Million |
| Dividends Paid | CN¥92.82 Million | CN¥77.99 Million | CN¥32.34 Million | CN¥10.78 Million | CN¥1.34 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥98.81 Million | CN¥77.27 Million | CN¥46.32 Million | CN¥47.50 Million | CN¥47.17 Million |
| Change in Cash | CN¥42.67 Million | CN¥56.77 Million | CN¥-63.20 Million | CN¥-110.14 Million | CN¥160.85 Million |
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Earnings History — EPS Actual vs. Analyst Estimates
Track Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 0.29 | — | — |
| Dec 31, 2025 | 0.25 | — | — |
| Sep 30, 2025 | 0.23 | — | — |
| Jun 30, 2025 | 0.21 | — | — |
| Apr 29, 2025 | 0.25 | — | — |
| Dec 31, 2024 | 0.15 | — | — |
| Oct 30, 2024 | 0.20 | — | — |
| Jul 09, 2024 | 0.20 | — | — |